UTMB part of national research group awarded $20 million HIV grant

November 25, 2014

The University of Texas Medical Branch is part of a collaboration led by the Oak Crest Institute of Science that received a $20 million grant from the National Institutes of Health to develop a novel intravaginal ring capable of delivering powerful antiretroviral drugs to prevent the spread of sexually transmitted HIV in women. The total award to UTMB is approximately $2.5 million.

After more than 40 years of research, prevention of HIV infection continues to be a critical global health priority. The World Health Organization reports that there are approximately 35 million people currently living with HIV, with about 70 percent from Sub-Saharan Africa.

Intravaginal rings, available commercially for contraception and hormone replacement therapy, show promise as a drug delivery system to prevent HIV infection, but most prototypes can't deliver multiple-drug combinations of the many available HIV antiretroviral drugs. While combinations of three antiretroviral drugs are highly successful in treatment of HIV/AIDS, their use in an intravaginal rings platform for HIV prevention has not been possible until now.

This project is, in large part, enabled by the pod-intravaginal ring platform. The team has shown that the platform can deliver five different drugs simultaneously and at independently controlled dosages, which is unlike any other device under development today. This program will allow rigorous testing of a large group of antiretroviral drugs in a systematic fashion to determine the best combination of drugs for HIV prevention.

The modular design of the pod-intravaginal ring also allows researchers to accelerate the development of prototypes, a critical element to testing many combinations as part of this program. Further, the technology platform has the crucial advantage of scalability in manufacturing, as the majority of the fabrication steps are identical regardless of the drug substances in the combination. This scalability and potential for economical manufacture will be crucial for any product to be used in the developing world.

Sustained-release drug delivery systems to prevent HIV infection are especially appealing for use in the developing world compared to daily therapies, as adherence is often an issue. Such devices are less expensive on a per-patient, per-day basis, they are capable of both rapid and sustained drug delivery for at least a month, and they sustain their effectiveness without refrigeration, which is an important consideration in resource-limited settings.

A multidisciplinary team from UTMB will lead projects to determine the drug safety and efficacy of the antiretroviral-releasing intravaginal ring by conducting in vitro, preclinical and clinical studies. Dr. Kathleen Vincent, UTMB assistant professor of Obstetrics and Gynecology, will lead the clinical studies that will establish the pharmacological properties and safety of the intravaginal rings in women. Dr. Richard Pyles, UTMB professor of pediatrics and microbiology and immunology, will lead the team utilizing the novel 3-D human vaginal culture model developed by his group to evaluate drug efficacy and toxicity in preventing HIV. Using advanced imaging techniques and models developed at UTMB, Dr. Massoud Motamedi, director of the UTMB center for biomedical engineering, will lead the preclinical animal studies supporting the pharmacological properties and safety evaluations. Dr. Monique Ferguson, associate professor of internal medicine, division of infectious diseases and director of the HIV pathogenesis laboratory, will provide expertise in virology and antiretrovirals. The work will also utilize research advances to evaluate the impact of both healthy and pathogenic vaginal bacterial communities on the delivered drugs.

"This will be the first clinical trial to evaluate the use of both the HIV treatment drugs tenofovir and emtricitabine delivered simultaneously through a vaginal ring over 28 days," said Vincent.

Pyles indicated that "vaginally applied medications offer advantages over systemic drug delivery because they directly protect the site of HIV transmission in addition to the protection given by a woman's healthy vaginal bacteria. This project will allow us, for the first time, to evaluate the impact of vaginally applied antiretroviral on the microbiome."

"Our goal is to empower women to protect themselves from HIV infection with the best biomedical solution," said Dr. Marc Baum, president of Oak Crest.
Other research teams on this project are from the CDC, Johns Hopkins Medical Institutions, Scripps Research Institute, University of California at Los Angeles and San Diego, Vanderbilt University, Miriam Hospital and Auritec Pharmaceuticals.

University of Texas Medical Branch at Galveston

Related HIV Articles from Brightsurf:

BEAT-HIV Delaney collaboratory issues recommendations measuring persistent HIV reservoirs
Spearheaded by Wistar scientists, top worldwide HIV researchers from the BEAT-HIV Martin Delaney Collaboratory to Cure HIV-1 Infection by Combination Immunotherapy (BEAT-HIV Collaboratory) compiled the first comprehensive set of recommendations on how to best measure the size of persistent HIV reservoirs during cure-directed clinical studies.

The Lancet HIV: Study suggests a second patient has been cured of HIV
A study of the second HIV patient to undergo successful stem cell transplantation from donors with a HIV-resistant gene, finds that there was no active viral infection in the patient's blood 30 months after they stopped anti-retroviral therapy, according to a case report published in The Lancet HIV journal and presented at CROI (Conference on Retroviruses and Opportunistic Infections).

Children with HIV score below HIV-negative peers in cognitive, motor function tests
Children who acquired HIV in utero or during birth or breastfeeding did not perform as well as their peers who do not have HIV on tests measuring cognitive ability, motor function and attention, according to a report published online today in Clinical Infectious Diseases.

Efforts to end the HIV epidemic must not ignore people already living with HIV
Efforts to prevent new HIV transmissions in the US must be accompanied by addressing HIV-associated comorbidities to improve the health of people already living with HIV, NIH experts assert in the third of a series of JAMA commentaries.

The Lancet HIV: Severe anti-LGBT legislations associated with lower testing and awareness of HIV in African countries
This first systematic review to investigate HIV testing, treatment and viral suppression in men who have sex with men in Africa finds that among the most recent studies (conducted after 2011) only half of men have been tested for HIV in the past 12 months.

The Lancet HIV: Tenfold increase in number of adolescents on HIV treatment in South Africa since 2010, but many still untreated
A new study of more than 700,000 one to 19-year olds being treated for HIV infection suggests a ten-fold increase in the number of adolescents aged 15 to 19 receiving HIV treatment in South Africa, according to results published in The Lancet HIV journal.

Starting HIV treatment in ERs may be key to ending HIV spread worldwide
In a follow-up study conducted in South Africa, Johns Hopkins Medicine researchers say they have evidence that hospital emergency departments (EDs) worldwide may be key strategic settings for curbing the spread of HIV infections in hard-to-reach populations if the EDs jump-start treatment and case management as well as diagnosis of the disease.

NIH HIV experts prioritize research to achieve sustained ART-free HIV remission
Achieving sustained remission of HIV without life-long antiretroviral therapy (ART) is a top HIV research priority, according to a new commentary in JAMA by experts at the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.

The Lancet HIV: PrEP implementation is associated with a rapid decline in new HIV infections
Study from Australia is the first to evaluate a population-level roll-out of pre-exposure prophylaxis (PrEP) in men who have sex with men.

Researchers date 'hibernating' HIV strains, advancing BC's leadership in HIV cure research
Researchers have developed a novel way for dating 'hibernating' HIV strains, in an advancement for HIV cure research.

Read More: HIV News and HIV Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.